Monday 6 July 2015, Amsterdam
The report, now available on ASDReports, “Biosurgery Market by Type (Surgical Sealants, Hemostatic Agents, Soft Tissue Attachments, Adhesion Barriers, Bone Graft Substitutes), by Application (Neurological, Cardiovascular, General, Orthopedic, Reconstructive) - Global Forecast to 2020” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.
This report studies the global biosurgery market during the forecast period of 2015 to 2020. The biosurgery market is expected to reach $25,635.01 Million by 2020 from $16,835.28 Million in 2015, at a CAGR of 8.8% from 2015 to 2020. Growth in this market is attributed to the increasing rate of obesity and other lifestyle disorders, increasing number of sports-related injuries, and growing aging population. However, increasing cost of surgical procedures and lack of reimbursements are expected to restrain the growth of this market to a certain extent.
The global biosurgery market is segmented by product, application, and region. This report also discusses the key market drivers, restraints, opportunities, and challenges for this market and its submarkets. On the basis of product type, the market is segmented into sealants, hemostatic agents, adhesion barriers, soft-tissue attachments, bone-graft substitutes, and staple-line reinforcement agents.
North America, a major global market for biosurgery, accounted for a major share of the biosurgery market, followed by Europe. However, emerging countries in the Asia-Pacific and the Rest of the World (Latin America) regions are expected to witness strong growth during the forecast period. Countries like India, China, and Brazil will majorly drive market growth owing to rising government investments for improvement of healthcare services, presence of a large patient population, and focus of leading players on capturing growth opportunities in these markets.
The key players in the biosurgery market include Baxter International Inc. (U.S.), C.R. Bard (U.S.), Johnson & Johnson (U.S.), Covidien plc (Ireland), Sanofi Group (France), B. Braun Melsungen AG (Germany), Atrium Medical Corporation (U.S.), Cryolife, Inc. (U.S.), Stryker Corporation (U.S.), and Hemostasis, LLC (U.S.).
Publish date : June 2015
Report code : ASDR-207700
Pages : 174